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Background: The incidence of anal cancer, a Human Papillomavirus (HPV)-related neoplasia, has been increasing in
recent decades, mainly in men who have sex with men (MSM). Cytological changes of the anal epithelium induced
by HPV can be detected through an anal pap smear. This study aimed to evaluate the prevalence and
epidemiological correlates of anal cytological abnormalities among relatively young MSM at risk for HIV-1 infection,
to help clarify whether or not this population deserves further investigation to assess the presence of anal cancer
precursor lesions.
Methods: MSM were recruited among attendees of a large STI clinic for a HIV-1 screening program. Anal samples,
collected with a Dracon swab in PreservCyt, were used both for liquid-based cytology and HPV testing by the
Linear Array HPV Genotyping Test. Data regarding socio-demographic characteristics and sexual behavior were
collected in face-to-face interviews.
Results: A total of 346 MSM were recruited (median age 32 years). Overall, 72.5% of the individuals had an anal
HPV infection, with 56.1% of them being infected by oncogenic HPV genotypes. Anal cytological abnormalities
were found in 29.8% of the cases (16.7% ASC-US and 13.1% L-SIL). Presence of ASC-US+ was strongly associated
with infection by any HPV type (OR=4.21, 95% CI: 1.97-9.23), and particularly by HPV 16 and/or 18 (OR=5.62, 95% CI:
2.33-13.81). A higher proportion of ASC-US+ was found in older MSM, in those with a higher number of lifetime
partners and in those with a history of ano-genital warts. However, none of these variables or the others analyzed
showed any significant association with abnormal cytological findings.
Conclusions: The presence of anal cytological abnormalities in about one third of the recruited MSM and their
strong association with HPV infection, in particular that caused by HPV 16 and/or 18, might provide a further
complement to the data that now support the introduction of HPV vaccination among MSM to protect them from
the development of HPV-associated diseases. Additional studies are needed to determine whether and how
screening for anal cancer precursor lesions should be performed in younger MSM.
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Anal cytology has been adopted in some clinical settings
as a standard procedure in individuals at risk for anal
cancer in order to detect its precursor lesions (high-
grade anal intraepithelial neoplasia, AIN). In fact, anal
cancer incidence, which is very low in the general popu-
lation [1], has been greatly increasing in recent decades,
particularly in certain populations [2]. Men having sex
with men (MSM) are at increased risk for the develop-
ment of this neoplasia. Among these subjects anal can-
cer incidence is similar to that of cervical cancer before
the introduction of cervical cytology screening, and is
twice as high in those that are HIV-1 infected [3,4]. In
general, history of receptive anal intercourse is strongly
associated with occurrence of anal cancer, so represent-
ing a main risk factor for Human Papillomavirus (HPV)
infection [5]. A persistent infection by HPV is now con-
sidered the cause of anal cancer, as well as of cervical
cancer. It can be assumed that 85% of anal cancer cases
occurring every year worldwide is caused by this virus as
a result of a sexually transmitted infection [6], although
HPV detection rate in this neoplasia varies according to
gender, HIV status and sexual behavior [2,7,8]. Some
studies have revealed the presence of HPV in virtually
all cases of anal cancer diagnosed in MSM [2,8], with
HPV16 being the most prevalent genotype (70-80%)
[9,10]. Based on a recent meta-analysis, more than 60%
of HIV-uninfected MSM have detectable anal HPV
infections, and almost 20% of them show anal canal
cytological abnormalities [11].
To date, only the New York State Department of
Health has released specific recommendations for anal
cancer screening in high-risk populations [12]. However,
despite the wide consensus on the need to screen HIV-
infected MSM, it is unclear if anal cytology should be
recommended for other populations of MSM, such as
younger individuals.
We conducted a cross-sectional study to assess the
prevalence of anal cytological abnormalities, evaluated
by liquid-based cytology, and anal HPV infection in a
population of relatively young MSM at risk for HIV-1
infection. In addition, we analyzed the possible associ-
ation of abnormal cytology with HPV infection and a
number of selected socio-demographic and behavioral
factors. These data should provide more information
concerning the burden of anal cytological abnormalities
among HIV-uninfected MSM.
Methods
Participant recruitment and questionnaires
Participants were recruited at the San Gallicano Derma-
tological Institute of Rome, Italy, from August 2009 to
November 2011. The study group included MSM
already participating in a longitudinal screening for HIV-1 and other sexually transmitted infections (STI), called
the COROH Project. Participants, ≥18-year-old, that had
not been previously vaccinated against HPV, were con-
sidered eligible according to the following criteria: 1. at
least one receptive/insertive anal intercourse with a man
in the preceding 6 months; 2. a HIV-1 negative antibody
test at enrollment; 3. absence of anal or genital warts at
enrollment; 4. no previous diagnosis of HPV-associated
ano-genital cancers.
All participants underwent an accurate inspection of
external genitalia and perianus in order to exclude the
presence of ano-genital warts. Data on medical history,
socio-demographic factors and sexual behavior were col-
lected in face-to face interviews, which were conducted
by a trained psychologist during the pre-HIV-test coun-
seling session.
The study was approved by the ethics committee of
the San Gallicano Dermatological Institute (Prot. CE/
564/11) and was performed in compliance with the Hel-
sinki Declaration. Informed consent was obtained from
all the participants.Anal sample collection and liquid-based cytology
Anal samples were collected as previously described
[13]. Briefly, a sterile Dracon swab was inserted and
rotated into the anal canal, and was then vigorously agi-
tated in the liquid cytology medium PreservCyt (Holo-
gic) to dislodge the epithelial cells. Cytological slides
were obtained using a ThinPrep 2000 processor (Holo-
gic) and the GYN protocol. Cytology was independently
interpreted by two certified cytopathologists, who were
blinded to the HPV test results. Cytological findings
were classified following the Bethesda 2001 guidelines,
also accepted for anal cytology [14]. The Bethesda sys-
tem includes the following categories: NILM (negative
for intraepithelial lesion or malignancy), ASC-US (atyp-
ical squamous cells of undetermined significance), L-SIL
(low-grade squamous intraepithelial lesion), or H-SIL
(high-grade squamous intraepithelial lesion). Samples
with poor cellularity or massive presence of squamous
anucleated cells were considered inadequate for the
cytological interpretation.HPV detection and genotyping
Molecular diagnosis of anal HPV infection was per-
formed as previously described [13]. Briefly, total nucleic
acids were extracted from 250 μl of the PreservCyt sam-
ple and screened for HPV DNA utilizing the Linear
Array® HPV Genotyping Test (Roche Diagnostics)
according to the manufacturer’s instructions. Results
were considered valid whenever the amplification of the
β-globin control and/or at least one HPV hybridization
band were observed. The risk associated with the
Table 1 Selected socio-demographic and behavioral
characteristics of the study participants
CHARACTERISTIC






high-school or less 52.4
university or more 47.6




Age at first intercourse with a man, median (IQR),
years (n=254)
19 (17-23)
N. lifetime male sex partners, median (IQR) (n=245) 50 (20-200)
N. male sex partners in previous 6 monthsb,
median (IQR) (n=264)
5 (2-10)
Partnership in previous 6 monthsb (%) (n=264)
steady partner only 14.0
steady and casual partners 23.9
casual partners only 62.1
Anal sex practices in previous 6 monthsb (%) (n=227)
insertive only 25.1
receptive only 8.8
receptive and insertive 66.1
Condom use during receptive intercourse in previous 6 monthsb (%) (n=170)
always 77.6
more than half times 15.9
up to half times 2.9
never 3.5





Gonorrhea (any site) 35.2
Ano-genital warts 46.3
a Low: <12,000 €; medium: 12,000-24,000 €; high: > 24,000 €.
b During the 6 months preceding the enrollment.
c STI diagnosed more than 6 months prior to enrollment.
d Proportions of MSM with a specific STI were calculated as a percentage of
the individuals with an STI history only; total sum of the percentages of
patients with an STI history exceeds 100% due to patients with more than one
STI.
Abbreviations: IQR, interquartile range; STI, sexually transmitted infections.
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cation adopted in one of our previous studies [13].
Data analysis
To evaluate the association between cytological out-
comes and the selected variables, crude odds ratios
(COR) and 95% confidence intervals (CI) were calculated
by univariate analysis using the SPSS+ package
(vers.17.0). ASC-US and L-SIL cases were combined for
purposes of analysis, and referred to as ASC-US+.
Results
Study population
A total of 346 HIV-uninfected MSM, who were mostly
Caucasian (97.1%), were enrolled. The characteristics of
the study population are shown in Table 1. The median
age was 32 years (IQR: 27-39) and the median age at
first intercourse with a man was 19 years (IQR: 17-23).
The median number of sexual partners lifetime and dur-
ing the previous 6 months were 50 (IQR: 20-200) and 5
(IQR: 2-10), respectively. Most of the participants had
only casual partners (62.1%) and engaged in both recep-
tive and insertive anal sex (66.1%).
Anal HPV infection
The presence of anal HPV was evaluated for all the par-
ticipants, and 251 of them (72.5%) were found to be
positive for the viral infection (any HPV type). High-
Risk (HR) HPV types were detected in 56.1% of the
cases, while 16.5% of the individuals were infected only
by Low-Risk (LR) HPV types (Table 2). A single infec-
tion (only one HPV type in a sample) was revealed in
35.1% of the HPV-positive individuals. HPV16 was the
most prevalent HPV type (18.2%, data not shown).
Anal cytology
Among the 346 anal samples collected, 47 (13.6%) were
considered inadequate for the cytological evaluation and
not included in the following analysis. Notably, a valid
HPV test result was obtained for all these cases, which
displayed a prevalence of infection that was similar to
the patients with a valid cytology report (data not
shown). Among the 299 adequate samples, cytological
investigation revealed normal cytology in 70.2% of cases,
while ASC-US and L-SIL were reported for 16.7% and
13.1% of cases, respectively (Figure 1). None of the
patients had a cytology report of H-SIL.
Abnormal anal cytology associated factors
Possible associations between abnormal anal cytology,
HPV infection, socio-demographic and behavioral char-
acteristics were analyzed. We found a statistically signifi-
cant association between abnormal anal cytology and
HPV infection (any type), the prevalence of cytological
Table 2 Anal HPV infection distribution and prevalence
overall, by HPV oncogenic risk, and number of genotypes
HPV infection N=346
n %
any type 251 72.5
any High-risk type 194 56.1
Low-risk only 57 16.5
High-risk only 81 23.4
Low-risk and High-risk 113 32.7





≥ 4 (up to 10) 51 20.3a
acalculated as a proportion of the HPV-positive individuals.
Table 3 Association between abnormal anal cytology and






Neg 10/83 (12.0) 1.00
Any HPV 79/216 (36.6) 4.21 (1.97-9.23)
LR-HPV only 20/52 (38.5) 4.56 (1.78-11.90)
Any HR-HPV 59/164 (36.0) 4.10 (1.88-9.17)
HPV 16 and/or 18 30/69 (43.5) 5.62 (2.33-13.81)
HR-HPV other than 16 and/or 18 29/95 (30.5) 3.21 (1.37-7.67)
Multiple HPV infection
No 21/77 (27.3) 1.00
Yes 58/139 (41.7) 1.91 (1.00-3.66)
Significant associations are highlighted in bold.
HR= High-Risk; LR= Low-Risk; COR= Crude Odds Ratio; CI= Confidence Interval.
*ASC-US+.
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duals and 36.6% among HPV-positive MSM (COR=4.21,
95% CI: 1.97-9.23) (Table 3). All HPV-negative patients
with cytological abnormalities had an ASC-US report.
Compared to HPV-negative individuals, increased pro-
portions of anal cytological abnormalities were evi-


















Figure 1 Distribution of anal cytological abnormalities among
299 HIV-uninfected MSM. Anal samples, collected with a Dracon
swab and stored in PreservCyt, were used for liquid-based cytology
to evaluate the presence of cytological abnormalities. These were
classified following the Bethesda 2001 guidelines.vs. 38.5%, COR=4.56, 95% CI: 1.78-11.90) and in those
with any HR type (12.0% vs. 36.0%, COR=4.10, 95% CI:
1.88-9.17). Importantly, MSM with HPV 16 and/or 18
anal infection showed the highest proportion of abnor-
mal cytology (43.5%), which was more than three times
higher than that found among HPV-negative partici-
pants (12.0%), COR=5.62, 95% CI: 2.33-13.81.
The prevalence of cytological abnormalities found
among individuals infected by LR-HPV only was not sig-
nificantly different from either that observed in MSM
infected by any HR-HPV (38.5% vs. 36.0%, COR=0.90
95%, CI: 0.45-1.80) or that observed in MSM infected by
HPV16 and/or 18 (38.5% vs. 43.5%, COR=1.23, 95% CI:
0.55-2.74).
The prevalence of cytological abnormalities was higher
in patients with a multiple infection than in those with a
single HPV type (41.7% vs. 27.3%), but this difference
was only marginally statistically significant (COR=1.91,
95% CI: 1.00-3.66).
The positivity for HPV16 and/or 18 was higher in L-SIL
than ASC-US cases (41.0% vs. 28.0%), while the positivity
for any other HR-HPV was similar in the two cytology
classes (33.3% and 32.0%, respectively, data not shown).
None of the selected socio-demographic and behavioral
characteristics was associated with a significant increase in
the prevalence of cytological abnormalities (Table 4). Al-
though the proportion of ASC-US+ cases found in older
MSM, in those with 20-49 lifetime sexual partners and in
those with a history of ano-genital warts was higher than
in the respective reference groups, in none of these cases
was the increase statistically significant.
Discussion
In the present study, we examined 346 MSM, with a
high risk for HIV infection and other STI, as other
Table 4 Association between abnormal anal cytology and







18-24 13/52 (25.0) 1.00
25-29 21/69 (30.4) 1.31 (0.54-3.20)
30-34 17/55 (30.9) 1.34 (0.53-3.42)
35-39 18/58 (31.0) 1.35 (0.54-3.40)
40-44 9/35 (25.7) 1.04 (0.35-3.09)
≥45 11/30 (36.7) 1.74 (0.59-5.13)
Education (n=221)
≤ High-school 33/115 (28.7) 1.00
>High-school 29/106 (27.3) 0.94 (0.50-1.76)
Incomea (n=221)
Low 33/110 (30.0) 1.00
Medium 26/93 (27.9) 0.91 (0.47-1.74)
High 5/18 (27.8) 0.90 (0.23-2.97)
Age at first intercourse with a man (n=221)
≥21 25/80 (31.2) 1.00
16-20 32/106 (30.2) 0.95 (0.48-1.87)
≤15 7/35 (18.9) 0.55 (0.19-1.55)
Lifetime number of male partners (n=213)
1-9 7/26 (26.9) 1.00
10-19 3/23 (13.0) 0.41 (0.06-2.15)
20-49 18/43 (41.9) 1.95 (0.61-6.45)
≥50 33/121 (27.3) 1.02 (0.36-2.96)
Number of sexual partners in previous 6 monthsb (n=230)
≤5 36/126 (28.6) 1.00
6-30 26/88 (29.5) 1.05 (0.55-1.99)
>30 4/16 (25.0) 0.83 (0.18-2.99)
Receptive anal sex in previous 6 monthsb (n=200)
No 12/46 (26.1) 1.00
Yes 41/154 (26.6) 1.03 (0.46-2.33)
Condom use during receptive anal sex (n=155)
Always 35/119 (29.4) 1.00
Sometimes/never 7/36 (19.5) 0.58 (0.21-1.55)
STI historyc (n=232)
No 37/140 (26.4) 1.00
Other than ano-genital wartsd 13/51 (25.5) 0.95 (0.43-2.10)
Ano-genital warts 16/41 (39.0) 1.78 (0.80-3.93)
a Low: <12,000 €; medium: 12,000-24,000 €; high: > 24,000 €.
b During the 6 months preceding the enrollment.
cSTI diagnosed more than 6 months prior to enrollment.
dGenital herpes, syphilis, gonorrhea (any site).
COR= Crude Odds Ratio; CI= Confidence Interval.
*ASC-US+.
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lence of anal cytological abnormalities and their associ-
ation with anal HPV infection, socio-demographic and
behavioral factors. Notably, this is one of the few studies
conducted on relatively young MSM (median age 32
years), while most of the previous studies focused on
older MSM [17,18]. Only a recent investigation was con-
ducted on very young HIV-negative MSM, their median
age being 22 years [19]. In addition, most of the research
data on HPV and anal lesions have been collected in
HIV-infected individuals, while this study focused on
HIV-uninfected patients. It also represents, to our know-
ledge, the largest investigation conducted in Italy on this
type of population.
This study was conducted on individuals with no vis-
ible HPV-related lesions in the anogenital area, which
was assessed through the careful inspection of the exter-
nal genitalia and perianal area. However, since no intra-
anal examination was performed, neither through a
digital rectal exam nor with high-resolution anoscopy
(HRA), it cannot be excluded that a proportion of the
individuals enrolled had intra-anal disease.
Our study showed that most of the subjects were
infected by HPV in the anal canal, with an overall preva-
lence of 72.5%, which is a higher value compared to
other cohorts of HIV-negative MSM [17,18]. The HPV
testing methods used may account for differences be-
tween these studies. In addition, our results may also de-
pend on the characteristics of the participants. In fact, as
already mentioned above, they showed a high risk for
HIV-1 infection and other STI [15,16]. HPV 16 was the
most prevalent type in the present study, confirming
that this genotype is the most frequently detected in the
anal canal of both men and women [18,20-23].
The same samples used to assess anal HPV infection
were also employed for liquid-based cytology. A propor-
tion of these samples was not adequate for the cyto-
logical interpretation (13.6%), either because of scant
cellularity or the massive presence of anucleated squa-
mous cells. Due to the modality of the present study,
conducted on STI Unit attendees who are not seen by
scheduled appointments, it must be noted that it was
not possible to ask the participants to adopt particular
precautions prior to the collection of the anal sample, as
otherwise indicated by the New York State Department
of Health AIDS Institute [12] and by the Anal Neoplasia
Clinic of the UCSF Comprehensive Cancer Center [24].
Therefore, patient behavior in the 24 hours preceding
the exam, such as use of lubricants, might have compro-
mised the quality of the specimen and might explain the
observed proportion of inadequate samples.
Notably, a valid HPV test result was obtained for all
samples, independently of the adequacy for the morpho-
logical evaluation, a fact that has also been observed in
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some samples lacked a sufficient number of nucleated
cells to allow the cytological interpretation, the material
was enough to obtain a valid HPV test result. This is
probably due to the high sensitivity of PCR-based meth-
ods, which are able to detect virtually one copy of DNA.
Among the participants with a valid cytology report,
we found abnormal anal cytology (ASC-US+) in 29.8%
of the cases. This finding is consistent with results of
previous studies conducted on HIV-uninfected MSM
that report a prevalence of anal cytological abnormalities
between 15 and 30% [26,27]. Notably, no H-SIL cases
were found in the present study. This finding is probably
due to the relatively young age of the participants, al-
though a previous study conducted on a cohort of 262
HIV-negative MSM with a mean age of 45 years also
failed to evidence any H-SIL cases at baseline [27]. Even
though only anal H-SIL is considered the real precursor
of anal cancer, it is worth noting that L-SIL may be clin-
ically important. Previous studies have shown that about
40% of HIV-negative homo/bisexual men with L-SIL at
baseline progressed to H-SIL within 2-4 years [26,27]. A
diagnosis of ASC-US may also hide SILs, a fact also evi-
denced in earlier studies [28,29]. These data underline
that all patients with a cytological report of ASC-US or
worse need a follow-up or accurate diagnostic investiga-
tions, which may include high-resolution anoscopy and
biopsy [30]. In fact, it is worth noting that one third of
ASC-US and L-SIL reports may be associated with high-
grade AIN diagnosed on a biopsy [31]. In addition, a re-
cent study evidenced AIN2+ in 20% of patients with a
negative cytology [32].
Importantly, infection by any HPV type was associated
with a 4-fold increased risk of having abnormal anal cy-
tology. MSM with a concurrent infection by LR-HPV
and HR-HPV types had an increased prevalence of ASC-
US+ compared to HPV-negative patients, but the highest
rate of cytological abnormalities was found in patients
with an infection by HPV16 and/or 18, which showed
the strongest association with abnormal anal cytology
(OR=5.62). Notably, previous studies have shown that
infections with HPV16 or 18 are significant risk factors
for the development of and progression to high-grade
AIN (AIN-2, 3) [33,34].
We found a borderline correlation between abnormal
anal cytology and HPV multiple infection. A previous
study showed that a multiple infection was present
with comparable frequency in men with normal cy-
tology and those with ASC-US/L-SIL [35]. However,
other reports have demonstrated an association be-
tween multiple HPV types and the presence of anal
lesions [29,36]. Therefore, the possible role of multiple
infections in the development of anal dysplasia remains
unclear.No association of abnormal cytology and age was
found, a fact already observed in other studies that evi-
denced a similar prevalence of anal cytological abnor-
malities in all age groups [37]. We previously showed
that HIV-negative MSM with a higher number of life-
time and recent sexual partners and having receptive
anal sex were at increased risk of HPV infection [13].
Yet, none of these factors was significantly associated
with abnormal anal cytology in the present study. It
must be noted that receptive anal intercourse was indi-
cated as a factor associated with anal cytological abnor-
malities in other studies [38]. However, it has been
previously shown that anal HPV infection is not exclu-
sively present in men reporting receptive sex [13,39,40],
because the anal infection can also be acquired through
other sexual practices. Therefore, it is not surprising to
find a similar prevalence of abnormal anal cytology
among MSM having and not having receptive inter-
course. In addition, data collected for the present study
referred to sexual behavior in the six months preceding
the enrollment, thus it cannot be excluded that MSM
not reporting receptive sex at the time of the interview
had previously engaged in this practice. Finally, it is pos-
sible that our ability to identify statistically significant
associations for some of the variables analyzed may have
been limited by the small number of patients included in
each group after stratification.
Conclusions
Our data show that about one third of the relatively
young HIV-uninfected MSM enrolled had anal cyto-
logical abnormalities. In addition, more than half of the
whole population was infected by HR-HPV genotypes.
Abnormal cytological findings were not significantly
associated with any of the socio-demographic and be-
havioral factors analyzed. Conversely, a strong associ-
ation with HPV infection, particularly with HPV 16 and/
or 18, was evidenced. Our findings might provide a fur-
ther complement to the large body of data that now sup-
port the introduction of HPV vaccination among MSM,
who might greatly benefit from the prevention of
HPV16/18 infection and related anal lesions.
All patients included in this study are currently in
follow-up in order to monitor the possible development
of anal dysplasia in cytologically negative participants
and to evaluate the actual presence of AIN in individuals
with abnormal anal cytology.
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